Source comparison
DAC vs No-DAC: The Half-Life Divide
The Drug Affinity Complex (DAC) is a maleimide-containing moiety that lets the CJC-1295 molecule covalently bind circulating albumin after injection, dramatically extending its half-life to a multi-day range. In the original healthy-adult study of albumin-bind
This comparison does not assign a generated winner or score.
- The Drug Affinity Complex (DAC) is a maleimide-containing moiety that lets the CJC-1295 molecule covalently bind circulating albumin after injection, dramatically extending its half-life to a multi-day range. In the original healthy-adult study of albumin-binding CJC-1295, single subcutaneous doses raised mean plasma GH 2- to 10-fold for six days or more and mean IGF-I 1.5- to 3-fold for nine to eleven days, with an estimated elimination half-life on the order of roughly six to eight days — a pharmacokinetic profile measured in days, not minutes.[1] The no-DAC form lacks that albumin anchor, so its action is measured in minutes to a couple of hours — a difference of roughly two to three orders of magnitude in duration between two molecules that share the same GHRH-analog backbone.
- This is the most consequential single fact a researcher can carry into any dosing discussion about “CJC-1295,” because the unqualified name is genuinely ambiguous: it can refer to either a compound that acts for half an hour or one that acts for a week and a half. When human study doses are quoted — as they are later in this article — they are almost always doses of the DAC form, and mapping them onto the no-DAC blend is a mistake.